Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch Health Companies Inc. (BHC) CEO Joe Papa on Q4 2020 Results - Earnings Call Transcript

Bausch Health Companies Inc (NYSE: BHC) is expanding its board of directors to accommodate two designees from activist investor Carl Icahn's Icahn Group, which owns 7.83% of the company's outstanding common stock. What Happened: The Quebec-based Bausch Health will add Brett Icahn and Steven Miller to its board in mid-March as independent directors, with each serving a term expiring at the company's 2021 annual meeting on April 27.

Bausch Health Adds 2 Directors Chosen By Carl Icahn: What Investors Need To Know

Bausch (BHC) delivered earnings and revenue surprises of 19.82% and -0.23%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Q4 Earnings Beat Estimates

Shares of Bausch Health Cos (NYSE:BHC) decreased 0.3% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 18.75% year over year to $1.33, which beat the estimate of $1.12.

Recap: Bausch Health Q4 Earnings

Bausch Health Companies Inc. reported Wednesday a narrower fourth-quarter net loss and revenue that declined from a year ago but topped expectations, as the COVID-19 pandemic led to "unprecedented challenges," but provided an upbeat full-year revenue outlook. The net loss was $153 million, or 43 cents a share, after a loss of $1.52 billion, or $4.30 a share, in the year-ago period.

Bausch Health reports narrower loss as revenue tops expectations, stock turns lower

Shares of Bausch Health Companies Inc. surged 2.9% toward a five-year high in premarket trading Wednesday, after the pharmaceuticals and medical devices company said it reached an agreement with billionaire activist investor Carl Icahn, and will add two of his nominees to its board of directors. The Icahn Group owns about 7.83% of the Bausch Health's shares outstanding.

Bausch Health stock surges toward 5-year high after agreement with activist investor Carl Icahn

Two New Directors to Be Appointed to Board Icahn to Support All Bausch Health Nominees for Election at 2021 Annual Meeting LAVAL, QB, Feb. 24, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") is pleased to announce that it will expand...

Bausch Health Announces Agreement With Carl C. Icahn

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Bausch Health (BHC) Ahead of Earnings?

Bausch Health is significantly undervalued based on a sum of the parts analysis, DOMO Capital believes shares should be closer to $80 per share. Numerous well-known activists (Paulson & Co., ValueAct, Glenview, GoldenTree Asset Management, and Icahn) own approximately 30% of the shares outstanding.

Bausch Health: Valued Significantly Below Sum Of The Parts And Generating Activist Interest

Legendary fund manager and activist investor Carl Icahn accumulated a 7.8% stake in Bausch Health Companies Inc (NYSE: BHC) and will likely leverage his status as the company's largest shareholder to push for change. Icahn's stake Icahn disclosed a 27.8 million share position in Bausch Health, formerly known as Valeant Pharmaceuticals in early February.

Here's why Carl Icahn is betting on Bausch Health

Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Bausch Health (BHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

DiaMedica Therapeutics Inc

iBio

Oncolytics Biotech, Inc.

Outlook Therapeutics Inc

iBio (NYSE: IBIO) shares are trading lower Wednesday after the company reported second-quarter earnings results. iBio's main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates.

Why Bausch Health, Oncolytics Biotech, And More Are Moving Today

Investors who have owned stocks since 2016 generally have experienced some big gains. In fact, the SPDR S&P 500 (NYSE: SPY) total return in the last five years is 131.9%.

$1,000, 5 Years Later: Valeant's Wild Ride To Bausch Health

The shares of Bausch Health Companies Inc (NYSE:BHC) are up 4.3% at $31.41 at last check, after Icahn Capital LP reported a 7.8% stake in the pharmaceutical concern, which is the equivalent of 27.8 million shares.

Pharma Stock Eyes 10th Straight on Shareholder Updates

Bausch Health stock got an added boost Friday after billionaire investor Carl Icahn disclosed a 7.8% stake in the pharmaceutical and medical device company.

Carl Icahn Discloses a Stake in Bausch Health. What It Means for the Stock.

Shares of Bausch Health Companies Inc. rallied 5.8% in premarket trading Friday, putting them on track for a 10th straight gain, after billionaire activist investor Carl Icahn disclosed that he had a acquired 27.8 million share, or 7.83% stake, in the pharmaceuticals and medical devices company. That's enough to make Icahn the company's largest shareholder, according to FactSet data.

Bausch Health rallies toward 10th straight gain after Carl Icahn discloses large stake

LAVAL, QC, Feb. 11, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") issued the following statement in response to the Schedule 13D filed by Icahn Capital LP filed earlier today: Bausch Health's Board of Directors and management team...

Bausch Health Responds To Schedule 13D Filing From Icahn Capital LP

Nicox Investors & Media Contact: Gavin Spencer communications@nicox.com +33 (0)4 97 24 53 00 Mary-Ann Chang mchang@lifesciadvisors.com +44 7483 284 853 Nicox Media France Contact: Sophie Baumont sophie@lifesciadvisors.com +33 6 27 74 74 49

Bausch Health Announces Vyzulta® (latanoprostene Bunod Ophthalmic Solution), 0.024%, is Now Approved in South Korea

LAVAL, Quebec, Jan. 27, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its fourth-quarter and full-year 2020 financial results on Wednesday, Feb. 24, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m. ET to...

Bausch Health Companies Inc. Will Release Fourth-Quarter And Full-Year 2020 Financial Results On February 24

Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.

Bausch Health (BHC) Dry Eye Treatment Study Enrollment Complete

Bausch + Lomb Will Also Host Presentation on Technologies that Can Help Create Efficiencies in Fitting Zenlens™ Scleral Lenses on Patients LAVAL, QC, Jan. 20, 2021 /PRNewswire/ -- Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch...

Bausch + Lomb Announces Scientific Data On Bausch + Lomb INFUSE™ Silicone Hydrogel Daily Disposable Contact Lenses To Be Presented At The Virtual Global Specialty Lens Symposium

The healthcare company released a positive preliminary update for the fourth quarter.

Why Bausch Health Stock Jumped 10% Today

JPMorgan Chase & Co

Bausch Health Companies Inc. (BHC) CEO Joe Papa Presents at 39th Annual JP Morgan Healthcare Conference (Transcript)

Bausch Health Corp. shares gained more than 5% in after-hours trading Tuesday after the company announced that its annual revenue will come in higher than its guidance. Bausch Health, formerly known as Valeant Pharmaceuticals before a scandal that led to large-scale changes at the company, said that fourth-quarter revenue would top $2.2 billion and lead annual sales to come in higher than the top end of its guidance range, $8 billion.

Bausch Health says annual revenue will exceed guidance, stock gains

LAVAL, QC, Jan. 6, 2021 /PRNewswire/ -- Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 13, 2021 at 10:00 a.m. ET. A...

News for Bausch Health Companies Inc Stock (BHC)